Divozilimab is under clinical development by Biocad and currently in Phase III for Neuromyelitis Optica (Devic’s Syndrome). According to GlobalData, Phase III drugs for Neuromyelitis Optica (Devic’s Syndrome) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Divozilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Divozilimab overview
Divozilimab (Ivlizi) is a monoclonal antibody. It is formulated as concentrate for solution for infusion for intravenous route of administration. Ivlizi is indicated for the treatment of relapsing multiple sclerosis, which includes relapsing-remitting multiple sclerosis and relapsing secondary progressive multiple sclerosis, with evidence of disease activity on clinical examination or on imaging studies.
Divozilimab is under development for the treatment of systemic sclerosis (scleroderma) and neuromyelitis optica spectrum diseases. It is administered through intravenous route in the form of solution. The therapeutic candidate is a humanized monoclonal antibody. It acts by targeting B lymphocyte antigen CD20.
Biocad overview
JSC Biocad (Biocad) is a biotechnology company that conducts research and development services. The company develops, manufactures, and distributes generic pharmaceutical products. Its products portfolio comprise rituximab, bevacizumab, trastuzumab, prolgolimab, levilimab, netakimab and eculizumab. Biocad develops products in the form of suppositories, spray, and drops. The compay provides products under the brands Avegra, Herticad, Gerticad, Forteka, Extimia and Leucostim. It manufactures products in the therapeutic areas such as oncology, rare disease, autoimmune diseases, and infectious diseases. The company’s R&D centers are located in Lyubuchany, Neudorf and Frontovaya. It operates in Brazil, China, Russia, the UAE and Vietnam. Biocad is headquartered in Saint-Petersburg, Russia.
For a complete picture of Divozilimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
